Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.19344 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neoadjuvant Cetuximab Leading to a Complete Pathologic Response in Locally Advanced Lip Squamous Cell Carcinoma.
Cureus
December 2024
Oncology and Hematology, Lucy Curci Cancer Center, Eisenhower Health, Rancho Mirage, USA.
Vermillion lip squamous cell carcinoma (SCC) is a rare cancer, currently grouped together with the cutaneous lip under the cutaneous squamous cell carcinoma (cSCC) system. Herein, we present a case of an 81-year-old male with locally advanced lower lip SCC involving the vermillion who achieved a complete pathologic response to neoadjuvant cetuximab after the failure of the programed cell death protein-1 (PD-1) inhibitor, cemiplimab. He was followed with clinical observation, with special attention to skin/mucosal surfaces.
View Article and Find Full Text PDFPrimary treatment of advanced ocular surface and adnexal squamous cell carcinoma with intravenous cemiplimab.
Orbit
December 2024
Department of Oculofacial Plastic and Orbital Surgery, Duke Eye Center, Durham, North Carolina, USA.
Development of diffuse cutaneous squamous cell carcinoma in situ after chemotherapy for ovarian carcinoma and remission with PD1-inhibitor.
Gynecol Oncol Rep
December 2024
Division of Gynecologic Oncology, University of Kentucky, Lexington, KY, United States.
Article Synopsis
- A 74-year-old woman was diagnosed with stage IV high grade serous ovarian cancer and malignant pleural effusion, showing PDL1 positivity.
- After starting standard chemotherapy (carboplatin and paclitaxel), she developed an itchy rash that was found to be a non-resectable in situ cutaneous squamous cell carcinoma (cSCC).
- A PD1-inhibitor was added to her treatment, leading to a complete response of both the ovarian cancer and the cSCC by the time of surgery.
Use of Preoperative Immunotherapy in Locally Advanced Unresectable Cutaneous Squamous Cell Carcinoma: A Case Report.
Case Rep Oncol
October 2024
Medical Oncology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
Introduction: Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. Surgery is the standard of care with curative intent of localized disease; however, for large head and neck cSCCs, it is associated with high morbidity. Cemiplimab, an antibody anti programmed cell death-1 (PD-1) protein, is effective in locally advanced unresectable or metastatic cSCC.
View Article and Find Full Text PDFInduction chemotherapy with cemiplimab in a patient with coexistent vulvar cancer and autoimmune disease: A case report.
Gynecol Oncol Rep
October 2024
Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine, United States of America.
There is limited data regarding the use of immunotherapy for patients with vulvar squamous cell carcinoma and coexisting autoimmune disease. Cemiplimab is a PD-1 inhibitor approved for use in patients with locally advanced and metastatic cutaneous squamous cell carcinoma. However, little is known about its efficacy in the setting of vulvar cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!